CD39

Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen’s 42nd Annual Health Care Conference

Retrieved on: 
Monday, February 28, 2022
GLOBE, Surface, CD73, GlaxoSmithKline, Event, Novartis, IND, CD39, IL-27, Conference, CCR8, PVRIG, Tumor microenvironment, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in the Novel Immuno-Oncology panel discussion at Cowens 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in the Novel Immuno-Oncology panel discussion at Cowens 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m.
  • A live webcast of the panel discussion will be accessible from the Events & Presentations page of the company's website.
  • A subsequent archived replay of the session will be available on the website for 30 days following the end of the conference.
  • Surface Oncologyis an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment.

Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, February 23, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lung, NSCLC, D, Income, Compliance, CD73, TIGIT, Collaboration, Investment, Research, PD-1, Prostate, Durvalumab, Clinical trial, NYSE, CRPC, Pancreatic cancer, BVF, Cancer, Exercise, Progression-free survival, IND, CD39, List of life sciences, Patient, Docetaxel, Renal medullary carcinoma, Congress, AstraZeneca, Colon, Medical imaging, Pharmaceutical industry

First patient was dosed in PACIFIC-8, a registrational Phase 3 study being conducted in collaboration with AstraZeneca.

Key Points: 
  • First patient was dosed in PACIFIC-8, a registrational Phase 3 study being conducted in collaboration with AstraZeneca.
  • Results from the randomized portion of ARC-8, including data on progression-free survival, are expected to be presented in 2H22.
  • Financial Results for the Fourth Quarter and Full Year Ended December 31, 2021
    Cash, cash equivalents and investments were $681.3 million as of December 31, 2021, compared to $735.1 million as of December 31, 2020.
  • Net income was primarily due to license revenue recognized upon closing of Gilead's exercise in December 2021 of its options.

Surface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology Summit

Retrieved on: 
Thursday, February 10, 2022
Tumor microenvironment, CD39, GLOBE, CCR8, CD73, GlaxoSmithKline, IL-27, Citigroup, IND, PVRIG, Surface, Novartis, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that company management will participate in a fireside chat during Citi's 2022 Virtual Immuno-Oncology Summit.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that company management will participate in a fireside chat during Citi's 2022 Virtual Immuno-Oncology Summit.
  • The presentation begins at8 a.m. ETonWednesday, February 16, 2022.
  • The live audio and subsequent archived webcast of the fireside chat will be accessible from the Events page of the companys website.
  • Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment.

Elpiscience Announces CDE Clearance of IND Application for Anti-CD39 Monoclonal Antibody ES002

Retrieved on: 
Wednesday, February 9, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Tumor microenvironment, CD39, Center for Drug Evaluation and Research, Cancer, IND, CMO, CDH, Patient, ATP, CDE, Mab, Center, Eli Lilly and Company, Hillhouse Capital Group, Adenosine, Fine chemical, Pharmaceutical industry

We are delighted that our IND application for ES002 is approved by the CDE, which follows the earlier IND and Phase I clinical study initiation in the US , said Dr. Steve Chin, CMO of Elpiscience.

Key Points: 
  • We are delighted that our IND application for ES002 is approved by the CDE, which follows the earlier IND and Phase I clinical study initiation in the US , said Dr. Steve Chin, CMO of Elpiscience.
  • We look forward to initiating the study in China and potential clinical benefits ES002 may offer for patients with solid tumors worldwide.
  • By blocking CD39 function, ES002 also stabilizes pro-inflammatory extracellular ATP (eATP) and restores anti-tumor immunity within the tumor microenvironment.
  • Elpiscience endeavors to advance at least one innovative molecule into the clinic each year to benefit cancer patients worldwide.

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors

Retrieved on: 
Thursday, January 20, 2022
Patient, Hillhouse Capital Group, CMO, Safety, ATP, GLOBE, Adenosine, CD39, Eli Lilly and Company, IND, CDH, Mab, Pharmacokinetics, Tumor microenvironment, Food and Drug Administration, Cancer, Food, FDA, Pharmaceutical industry

Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for ES002 in September 2021.

Key Points: 
  • Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for ES002 in September 2021.
  • We are very pleased to see ES002 enter clinical trial testing in the United States, said Steve Chin, CMO of Elpiscience.
  • This is an important milestone for Elpiscience as we seek to develop innovative and differentiated cancer immunotherapies.
  • Elpiscience endeavors to advance at least one innovative molecule into the clinic each year to benefit cancer patients worldwide.

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors

Retrieved on: 
Thursday, January 20, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Molecule, Patient, Hillhouse Capital Group, CMO, Safety, ATP, Adenosine, CD39, Eli Lilly and Company, IND, CDH, Mab, Pharmacokinetics, Tumor microenvironment, Food and Drug Administration, Cancer, Food, Clinic, FDA, Pharmaceutical industry

Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for ES002 in September 2021.

Key Points: 
  • Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for ES002 in September 2021.
  • We are very pleased to see ES002 enter clinical trial testing in the United States, said Steve Chin, CMO of Elpiscience.
  • Elpiscience is a clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy to benefit cancer patients worldwide.
  • It has four molecules in clinical trials (ES002, ES101, ES102, and ES104), and endeavors to clinically advance at least one innovative molecule a year.

Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones

Retrieved on: 
Monday, January 10, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, CRPC, Safety, Arcus, Colorectal cancer, NSCLC, List of life sciences, PD-L1, Cancer, Patient, IND, Lung, Key Stage 3, Program, Pancreatic cancer, Initiate, CRC, Research, NYSE, Taiho, Docetaxel, Durvalumab, CD39, Gilead Sciences, Achievement, Inflammation, AstraZeneca, Progression-free survival, TKI, Fine chemical, Pharmaceutical industry, Medical imaging, Medical device

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today provided updates on clinical programs and key milestones anticipated in 2022.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today provided updates on clinical programs and key milestones anticipated in 2022.
  • Data from ARC-7, an ongoing randomized 150-patient three-arm study in first-line PD-L150% NSCLC, including progression-free survival data, are expected to be presented in 2H22.
  • Additional clinical studies for etrumadenant-based combinations, including the triplet of etrumadenant plus domvanalimab and zimberelimab, are being planned for 2022.
  • With this cash position and 50/50 cost sharing with Gilead for the joint development programs, Arcus plans to expand its clinical development programs and anticipates cash utilization of $275-325 million in 2022.

Surface Oncology Appoints Denice Torres as Chair of the Board of Directors

Retrieved on: 
Wednesday, December 15, 2021
PVRIG, Acquisition, Saint John's University, Risk, McNeil Consumer Healthcare, Notre Dame College, Janssen Pharmaceuticals, MBA, Shannon, Organization, Forward-looking statement, Psychology, Tumor microenvironment, Growth, IL-27, IND, U.S. Securities and Exchange Commission, Ball State University, CCR8, Ball, Johnson & Johnson, Security (finance), GLOBE, Social change, University of Colorado Denver Business School, Prediction, Eli Lilly, CD39, University, Woman, COVID-19, Medical device, Marketing, Bristol Myers Squibb, University of Massachusetts Medical School, GlaxoSmithKline, CNS, Private Securities Litigation Reform Act, Industry, CD73, Annual report, Bluebird bio, McGrath, Novartis, Patient, Leadership, Management, Pharmaceutical industry, Indiana University, Northeastern University, Surface

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointments of Denice Torres to chair of the board of directors and Ben Hickey to board director. In conjunction with the board appointments, Jeff Goater will transition to board director. The company also announced internal promotions of key senior executives, naming Lisa McGrath chief people officer and Shannon Devens senior vice president, development operations.

Key Points: 
  • Since joining our board earlier this year, Denice has had a significant impact and brought invaluable perspective through a critical period of development for Surface.
  • Additionally, I am pleased to welcome Ben Hickey to our board of directors.
  • Ben is an accomplished leader in the oncology space with significant experience leading organizations through commercial readiness and successful product launches.
  • I also want to thank Jeff Goater for the guidance and thought leadership he has provided throughout his tenure as chair.

Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Retrieved on: 
Monday, December 6, 2021
Patient, Private Securities Litigation Reform Act, PVRIG, NSCLC, European Society for Medical Oncology, Pancreatic cancer, Security (finance), Safety, Surface, PD, PK, Annual report, Forward-looking statement, Novartis, CCR8, Cancer, Tumor microenvironment, IL-27, IND, Pharmacokinetics, Clinical trial, ATP, U.S. Securities and Exchange Commission, CD73, COVID-19, Large-cell lung carcinoma, Pembrolizumab, CD39, Research, Neoplasm, Adenosine, Risk, GLOBE, Orphan drug, GlaxoSmithKline, B cell, FDA, PD-1, Congress, Disease, Medical imaging, Pharmaceutical industry

The recommended Phase 2 dose for SRF617 monotherapy has been determined to be 1400 mg Q2W based on aggregate review of safety, clinical PK/PD and preclinical data.

Key Points: 
  • The recommended Phase 2 dose for SRF617 monotherapy has been determined to be 1400 mg Q2W based on aggregate review of safety, clinical PK/PD and preclinical data.
  • SRF617 is well-tolerated at doses that sustain full target occupancy throughout the dosing interval and demonstrate dose-dependent loss of CD39 on B cells.
  • Early data from a patient undergoing paired tumor biopsy show marked decrease of CD39 expression in the tumor microenvironment following SRF617 treatment.
  • The recommended Phase 2 dose for SRF617 in combination with pembrolizumab has also been determined to be 1400 mg Q2W.

Surface Oncology Named a 2021 Top Place to Work by the Boston Globe

Retrieved on: 
Friday, December 3, 2021
Private Securities Litigation Reform Act, PVRIG, Security (finance), The Boston Globe, Surface, Workforce, Annual report, Forward-looking statement, Novartis, CCR8, Cancer, Tumor microenvironment, IL-27, IND, U.S. Securities and Exchange Commission, CD73, COVID-19, Trust, CD39, Risk, GLOBE, Work, GlaxoSmithKline, Public relations, Pharmaceutical industry

CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Surface Oncology , a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company was named one of the Top Places to Work in Massachusetts in 2021 by the Boston Globe.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Surface Oncology , a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company was named one of the Top Places to Work in Massachusetts in 2021 by the Boston Globe.
  • Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them besttheir employees.
  • Surface is honored to be recognized by the Boston Globe as a Top Place to Work and will continue to foster an organizational culture rooted in trust, inclusivity, mutual respect and collaboration, said Rob Ross, M.D., chief executive officer at Surface Oncology.
  • In addition, any forward-looking statements contained in this press release are based on assumptions that Surface Oncology believes to be reasonable as of this date.